메뉴 건너뛰기




Volumn 325, Issue 2, 2021, Pages 184-186

Clinical Implications of Removing Race from Estimates of Kidney Function

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; WARFARIN; CREATININE;

EID: 85097420620     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2020.22124     Document Type: Letter
Times cited : (110)

References (6)
  • 1
    • 85067055289 scopus 로고    scopus 로고
    • Reconsidering the consequences of using race to estimate kidney function
    • 31169890
    • Eneanya ND, Yang W, Reese PP. Reconsidering the consequences of using race to estimate kidney function. JAMA. 2019; 322 (2): 113-114. 31169890
    • (2019) JAMA , vol.322 , Issue.2 , pp. 113-114
    • Eneanya, N.D.1    Yang, W.2    Reese, P.P.3
  • 2
    • 85087824354 scopus 로고    scopus 로고
    • Hidden in plain sight - Reconsidering the use of race correction in clinical algorithms
    • 32853499
    • Vyas DA, Eisenstein LG, Jones DS. Hidden in plain sight-reconsidering the use of race correction in clinical algorithms. N Engl J Med. 2020; 383 (9): 874-882. 32853499
    • (2020) N Engl J Med , vol.383 , Issue.9 , pp. 874-882
    • Vyas, D.A.1    Eisenstein, L.G.2    Jones, D.S.3
  • 3
    • 85096370022 scopus 로고    scopus 로고
    • KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease: Summary of recommendation statements
    • doi: 25598998
    • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease: summary of recommendation statements. Kidney Int Suppl (2011). 2013; 3 (1): 5-14. doi: 10.1038/kisup.2012.77 25598998
    • (2013) Kidney Int Suppl (2011) , vol.3 , Issue.1 , pp. 5-14
  • 4
    • 85099603103 scopus 로고    scopus 로고
    • 42 CFR §410. Accessed October 6, 2020
    • Code of Federal Regulations. Supplementary Medical Insurance (SMI) Benefits. 42 CFR §410. Accessed October 6, 2020. https://www.law.cornell.edu/cfr/text/42/part-410
    • Supplementary Medical Insurance (SMI) Benefits
  • 6
    • 85093831870 scopus 로고    scopus 로고
    • Race and the false precision of glomerular filtration rate estimates
    • doi: 32805131
    • Sehgal AR. Race and the false precision of glomerular filtration rate estimates. Ann Intern Med. 2020; 173 (12): 1008-1009. doi: 10.7326/M20-4951 32805131
    • (2020) Ann Intern Med , vol.173 , Issue.12 , pp. 1008-1009
    • Sehgal, A.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.